Pediatric voiding dysfunction: current evaluation and management.
Voiding dysfunction and urinary incontinence in children is common. Both are associated with significant effects on quality of life and comorbidities, including urinary tract infections (UTIs) and constipation. A thorough history, physical examination, and non-invasive evaluation are essential in determining the etiology. Interventions, such as behavioral therapy/biofeedback and pharmacologic therapies, are primary treatments. Prevalence rates, current evaluation, and management techniques are discussed in this article.
Ellsworth
Pamela
P
Urological Association, Inc., Rhode Island Hospital, Providence, RI, USA.
Caldamone
Anthony
A
D000317:Adrenergic alpha-Antagonists / Q000627:therapeutic use; D001521:Behavior Therapy; D019274:Botulinum Toxins, Type A / Q000627:therapeutic use; D002648:Child; D018680:Cholinergic Antagonists / Q000627:therapeutic use; D004599:Electric Stimulation Therapy; D004567:Electrodes, Implanted; D006801:Humans; D008487:Medical History Taking; D019060:Minimally Invasive Surgical Procedures; D009017:Morbidity; D009465:Neuromuscular Agents / Q000627:therapeutic use; D009730:Nursing Assessment; D010371:Pediatric Nursing; D010808:Physical Examination; D015995:Prevalence; D011788:Quality of Life; D014039:Toilet Training; D016896:Treatment Outcome; D014555:Urination Disorders / Q000145:classification / Q000175:diagnosis* / Q000453:epidemiology / Q000628:therapy*; D014563:Urodynamics; D014567:Urography; D014718:Vesico-Ureteral Reflux
D000317:Adrenergic alpha-Antagonists; D018680:Cholinergic Antagonists; D009465:Neuromuscular Agents; D019274:Botulinum Toxins, Type A